Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.8452W HIGH $9.55
Volume
681.11 K
Value Traded
11.60 M
Short % Float
12.77%
-5.1%Week
-60.37%1 Month
-87.3%3 Month
-86.06%6 Month
-91.27%5 Year
+7,916.67%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
32.92 M
EPS (TTM)
-3.93
P/E Ratio
-
Ent. Value
25.26 M
Total Shares
76.94 M
Float Shares
69.66 M
Insiders
9.42%
Institutions
92.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ACH Catalyst Timeline
Dated clinical, regulatory and corporate events for Accendra Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Accendra Health, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How ACH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ACH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Galloway Heath HOfficer (EVP,General Counsel & CorpSecy) | Disposition | -1,822 166,306 held | $2.91 | 05/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ACH for Q2 2026. | ||||
ACH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACH ranks across every disease it competes in
Competitive Position is a premium feature
See how ACH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACH News
ACH▼ -3.4%today
Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard
Accendra Health, Inc. received a notice from the NYSE regarding non-compliance with listing standards due to its Class A Common Stock trading below $1.00 for 30 consecutive days. The company plans to address this deficiency and aims to return to compliance with NYSE standards. This proactive approach highlights their commitment to maintaining their listing.
Read more →ACHAccendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth
Accendra Health has appointed Kenneth Gardner-Smith as its new President and CEO, effective early in the fourth quarter of 2026. He will take over from Edward A. Pesicka, who is retiring. Gardner-Smith, a current board member since March 2022, is expected to leverage his extensive experience in patient care operations to lead the company’s growth.
Read more →ACH▲ +12.5%on this news· ran to +38% by day 3
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
Accendra Health has announced updates regarding its capital allocation strategy and the timeline for CEO succession. In light of recent market conditions, the company has opted not to pursue an at-the-market issuance program, which was designed to allow for opportunistic equity issuance. This decision aims to prioritize stakeholder interests amid current market challenges.
Read more →ACH▼ -50%on this news· ran to -61% by day 3
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value
Accendra Health, Inc. has adopted a Tax Asset Preservation Plan to safeguard long-term shareholder value. This plan aims to preserve the company's net operating loss carryforwards and other tax attributes, which is crucial for maintaining financial health. The Board of Directors believes this strategy will benefit shareholders in the long run.
Read more →ACH▼ -50%on this news· ran to -61% by day 3shared move
Accendra Health Reports Second Quarter 2026 Financial Results
Accendra Health, Inc. reported its financial results for Q2 2026, highlighting progress in separating from Owens & Minor. The results reflect the company's continuing operations, which include the former Patient Direct segment. The company is also focusing on strengthening its commercial payer relationships.
Read more →ACH▼ -50%on this news· ran to -61% by day 3shared move
Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
Accendra Health's CEO, Edward A. Pesicka, has announced his intention to retire by the end of 2026 after more than seven years in the role. He will also step down from the Board of Directors before the year concludes. The company has a strong succession planning process to ensure a smooth leadership transition.
Read more →ACHAccendra Health Announces Leadership Appointments in IT and Procurement
Accendra Health has announced significant leadership appointments in its Information Technology and Procurement sectors. These changes aim to strengthen the company's operational foundation and align its strategy with execution. The appointments are part of Accendra's transition to a dedicated home-based care organization, emphasizing its commitment to advancing healthcare.
Read more →ACHAccendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call
Accendra Health, Inc. has announced the release date for its second quarter 2026 earnings report, which will be available on August 10, 2026, before market trading begins. The company will also hold a conference call for investors and analysts at 8:00 a.m. EDT on the same day, offering a platform for discussion and inquiries.
Read more →ACHAccendra Health Announces Expiration and Final Results of Offers and Consent Solicitations
Accendra Health has announced the expiration and final results of its offers and consent solicitations. The details regarding the outcomes of these solicitations have not been disclosed in the provided text. Further information may be required for a comprehensive understanding of the implications.
Read more →ACHAccendra Health Announces Early Results of Offers and Consent Solicitations
Accendra Health has announced early results of its offers and consent solicitations. However, the article does not provide specific details regarding the outcomes or implications of these results. The announcement appears to be part of ongoing corporate activities.
Read more →ACHAccendra Health Announces Offers and Consent Solicitations
Accendra Health has announced offers and consent solicitations. However, the article does not provide further details on the nature or implications of these announcements. The lack of specific information leaves the overall sentiment neutral.
Read more →ACH▲ +8.7%on this news
Accendra Health Reports First Quarter 2026 Financial Results and Announces Comprehensive Balance Sheet Optimization Transaction
Accendra Health has released its financial results for the first quarter of 2026, alongside a significant balance sheet optimization transaction. The report highlights the company's efforts to enhance its financial position. Further details on the transaction and its implications for future performance were not provided.
Read more →ACH▲ +8.7%on this news
Project Huskies Management Presentation May 2026 THIS PRESENTATION MAY CONTAIN MATERIAL NON-PUBLIC INFORMATION CONCERNING THE COMPANY (AS DEFINED HEREIN) AND ITS SUBSIDIARIES. BY ACCEPTING THIS PRESENTATION, THE RECIPIEN
Accendra Health has released a confidential management presentation outlining various aspects of the company and its strategic plans as of May 2026. The presentation emphasizes that it may contain material non-public information and outlines confidentiality obligations for recipients. Additionally, it includes forward-looking statements related to the company's performance and expectations, though the company disclaims any assurances regarding these projections. Potential investors are warned about the uncertainties surrounding these forward-looking statements and encouraged to review risk factors in their SEC filings.
Read more →ACHAccendra Health Reports Fourth Quarter 2025 Financial Results Completed Sale of Products & Healthcare Services Business On December 31, 2025
Accendra Health, Inc. reported its financial results for the fourth quarter of 2025, highlighting the completion of the sale of its Products & Healthcare Services segment. This transaction is expected to pave the way for a more focused operation, with the company's leadership expressing optimism about future growth and value creation. Despite a strong revenue performance in the fourth quarter, the company still reported a loss from continuing operations, indicating ongoing financial challenges. The outlook for 2026 includes goals for improved cash flow and balance sheet optimization amidst potential market uncertainties.
Read more →ACH▼ -74.3%on this news
Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity The Transaction Includes the Owens & Minor Brand, and the Remaining Company Will Become Accendra Health
Owens & Minor, Inc. has completed the sale of its Products & Healthcare Services segment to Platinum Equity for $375 million, marking a strategic shift for the company. Following this transaction, the company will be renamed Accendra Health, focusing on home-based care solutions. The leadership believes this move will strengthen their market position and operational execution in supporting chronic condition management. The sale is also structured to preserve certain tax attributes beneficial for the company’s future.
Read more →ACH▼ -74.3%on this newsshared move
Owens & Minor Announces Corporate Name Change to Accendra Health, Inc. Accendra Health To Trade Under the "ACH" Symbol on the New York Stock Exchange
Owens & Minor, Inc. has announced that it will change its name to Accendra Health, Inc. effective December 31, 2025. This name change is part of the company's strategic shift to focus on the home-based care market, while continuing to use current brands like Apria and Byram Healthcare. Along with the name change, the company will adopt the ticker symbol "ACH" on the New York Stock Exchange starting January 2, 2026. The organization aims to enhance its market position and reflect its commitment to high-quality patient care through this rebranding.
Read more →ACH▼ -74.3%on this newsshared move
Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
Owens & Minor, Inc. announced its participation in two investor conferences on December 2, 2025, in Miami and Boca Raton, Florida. Key executives, including CEO Ed Pesicka and CFO Jon Leon, will be involved in discussions and one-on-one meetings with investors. These events provide a platform for the company to communicate its strategic goals and engage with stakeholders.
Read more →ACH▼ -74.3%on this newsshared move
Owens & Minor Reports Third Quarter 2025 Financial Results Signed Definitive Agreement for the Sale of Products & Healthcare Services Segment
Owens & Minor, Inc. has reported its financial results for the third quarter of 2025, showing a focus on transitioning to a pure-play home-based care business following the sale of its Products & Healthcare Services segment. The company expressed confidence in its growth strategy centered around its Patient Direct platform and has engaged in a nationwide preferred provider partnership. However, Owens & Minor faced a considerable net loss for the quarter, raising concerns about its financial stability amidst ongoing restructuring efforts. The outlook for future financial results is clouded by uncertainties regarding GAAP measures due to unpredictable costs.
Read more →ACH▼ -74.3%on this newsshared move
Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment to Platinum Equity for $375mm in Cash and a Retained Equity Stake Transforms Owens & Minor into a Pure Play Market Leader in t
Owens & Minor has finalized an agreement to divest its Products & Healthcare Services segment to Platinum Equity for $375 million in cash, while retaining a 5% equity stake. This strategic move aims to simplify Owens & Minor's business model and enhance its focus on the burgeoning home-based care market. The transaction also includes preserving essential tax attributes worth over $150 million, highlighting the financial prudence of the deal. The expected closing of this transaction is slated for the end of 2025, pending customary regulatory approvals.
Read more →ACH▼ -74.3%on this newsshared move
Owens & Minor Reports Second Quarter 2025 Financial Results Classified Products & Healthcare Services Segment as Discontinued Operations
Owens & Minor, Inc. reported its financial results for the second quarter of 2025, indicating a loss from continuing operations and a classification of its Products & Healthcare Services segment as discontinued operations due to an impending sale. The Patient Direct segment showed solid performance, leading the company to position itself as a pure-play entity in this space. While there are positive expectations for future growth in the Patient Direct area, significant financial losses and ongoing uncertainties related to the divestiture raise concerns about the company's outlook.
Read more →About Accendra Health, Inc.
Headquarters4435 WATERFRONT DRIVE, GLEN ALLEN, VA
BIOPHARMAWATCH ELITE PLUS
Trade the next ACH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime